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Chronic bronchitis is common among adults and infectious exacerbations contribute considerably to morbidity and
mortality. We aimed to compare the safety and ecacy of moxifloxacin to clarithromycin for the treatment of
patients with acute bacterial exacerbations of chronic bronchitis (ABECB) using a prospective, randomized,
double-blind, parallel group trial.
Between November 21, 1996 and April 7, 1998, 936 patients with acute exacerbations of chronic bronchitis
(AECB) were enrolled at 56 centers across the United States of which 491 (52%) had ABECB (i.e. pretherapy
pathogen).
Patients were randomized to either oral moxifloxacin 400 mg administer once daily, for either 5 or 10 days, or
clarithromycin 500 mg bid for 10 days. For the purpose of study blinding, the patients taking moxifloxacin received
placebo to maintain uniform dosing.
The main outcome measures were bacteriological response at the end of therapy (post-therapy days 0–6) and
follow-up (7–17 days post-therapy) visits, as well as overall clinical response, clinical response at the end of therapy
and clinical response at follow-up. Two patient populations were analyzed: ecacy-valid (i.e., those with a
pretherapy pathogen) and intent-to-treat (i.e., all subjects that took drug).
In 420 ecacy valid patients with a pretherapy organism, overall clinical resolution was 89% for 5 days
moxifloxacin vs. 91% for 10 day moxifloxacin vs. 91% for 10 day clarithromycin. Bacteriological eradication rates
at the end of therapy were 94% and 95% for 5-day moxifloxacin and 10-day moxifloxacin, respectively, and 91%
for the clarithromycin group. Eradication rates at follow-up were 89% and 91% for 5-day moxifloxacin and 10-day
moxifloxacin respectively, and 85% for the clarithromycin group. Among 926 intent-to-treat patients (312 5-day
moxifloxacin, 302 10-day moxifloxacin and 312 clarithromycin), drug-related events were reported for 26%, 30%
and 35%, respectively.
Moxifloxacin 400 mg once daily, as a 5 or 10 day regimen, was found to be clinically and bacteriologically
equivalent to 10 day clarithromycin for the treatment of ABECB. Given its favorable safety and tolerability profile,
moxifloxacin administered once daily for 5 days may be as eective and a more convenient treatment than a
standard course of clarithromycin for patients with ABECB.
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Almost one in four adult Americans experience symptoms
of chronic bronchitis (1,2), accounting for approximately
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Causeway Street, Boston, MA 02114, U.S.A.0954-6111/00/010018+10 $35?00/012 million physician visits annually, at a cost of more than
$300 million per year (3). Acute exacerbations of chronic
bronchitis (AECB) are a frequent complication of this
condition and are often precipitated by environmental
agents (e.g. air pollution, smoking), allergy, alcohol
consumption, secretion clearance problems, acute viral
respiratory infections, or decreases of pulmonary medica-
tions (4,5). Infection, identified by significant numbers of
bacteria, is the etiology in approximately 50–60% of AECB
episodes (4,5,6). While some patients may resolve their
bacterial infection without anti-microbial therapy, their
illness can be protracted and may require hospitalization
following the development of pneumonia and respiratory
insuciency. Accordingly, patients with acute bacterial# 2000 HARCOURT PUBLISHERS LTD
MOXIFLOXACIN 5-DAY THERAPY BRONCHITIS 19exacerbations of chronic bronchitis (ABECB) who present
with increased dyspnea, cough, purulent sputum produc-
tion and evidence of bacterial infection can benefit from
anitbacterial therapy (4,5). Unfortunately, the decision to
initiate antimicrobial therapy can be dicult because
symptoms associated with ABECB are indistinguishable
from those associated with acute exacerbations due to non-
bacterial etiologies (5). In a recent meta-analysis, a small
benefit to antibiotics over placebo in treatment of
unspecified AECB was documented, as well as evidence
that peak flow measurements improved significantly in
antibiotic-treated patients (8).
The pathogens most commonly associated with ABECB
have been Haemophilus influenzae, Streptococcus pneumo-
niae and Moraxella catarrhalis, with Haemophilus parain-
fluenzae appearing more frequently in recent years (4,5,9).
Over the past decade, the levels of resistance to frequently
prescribed antibiotics among these pathogens have risen
significantly. In the U.S., almost every clinical isolate ofM.
catarrhalis produces -lactamase, approximately 40% of H.
influenzae isolates are -lactamase producers and resistant
strains of S. pneumoniae resistant to -lactams and
macrolides have been increasing worldwide (10,11,12). By
the year 2000, it has been estimated that approximately
50% of H. influenzae isolates will produce -lactamase (10).
Accordingly, eorts to combat bacterial resistance have
focused on the development of new antimicrobials with
broader spectra of activity with less indication to develop
resistance. Physicians should consider the local patterns of
resistance when selecting an antibiotic for treatment of
ABECB, as many older agents, such as amoxicillin and
trimethoprim/sulfamethoxazole, may no longer be eective.
Moxifloxacin in a new 8-methoxyquinolone with excel-
lent in vitro activity against commonly encountered Gram-
positive and Gram-negative respiratory tract pathogens
(13,14). It has excellent in vitro activity against pneumo-
coccal strains resistant to -lactam and macrolide anti-
biotics and good activity against atypical respiratory tract
pathogens (13,15,16). Against S. pneumoniae, the MIC90 for
moxifloxacin is 0.25 mg l71, which is at least four to eight-
fold more active than ciprofloxacin and levofloxacin and at
least as active as trovafloxacin (13). Moxifloxacin has
reported MIC values of 006 g ml71 for both H. influenzae
and M. catarrhalis (13). Importantly, -lactamase activity
or macrolide resistance mechanisms do not influence the in
vitro activity of moxifloxacin.
Based on moxifloxacin’s in vitro activity against respira-
tory pathogens and its pharmacokinetic profile (17,18), a
dose of 400 mg once daily should provide serum levels for
adequate bactericidal activity for patients with ABECB.
Hence, the purpose of the current study was to assess the
bacteriological ecacy and safety, as well as compare the
clinical ecacy, of treatment with moxifloxacin (400 mg
once daily) for 5 or 10 days with that of clarithromycin (500
mg twice daily) for 10 days in patients with ABECB. The
once daily administration schedule and option of a shorter,
5-day course of therapy with moxifloxacin may have
compliance advantages over existing therapies. Although
this study was undertaken, in part, to satisfy registration
requirements for the licensing of new drugs, the primarypopulation for analysis for this manuscript was patients
with documented pretherapy bacterial etiologies. We chose
to focus our analyses on those patients with a documented
bacterial infection since this subgroup should best deter-
mine the eectiveness of any antimicrobial.
Methods
STUDY DESIGN
This was a double-blind, randomized, active controlled,
parallel-group trial designed to compare moxifloxacin,
using a 5-day and 10-day regimen, to 10 day clarithromy-
cin, in the treatment of ABECB. Patients were enrolled at
clinical sites randomly distributed throughout North
America. These sites were clinic-based and managed by
physicians who included primary care physicians, pulmo-
nologists and infectious disease specialists. The trial format
was conducted according to the guidelines described by the
Committee on the Consolidation of Standards for Report-
ing Trials (19).
STUDY POPULATION
Patients eligible for inclusion in the study were 18 years or
older with underlying chronic bronchitis as defined by the
daily production of sputum on most days for at least 3
consecutive months for more than 2 consecutive years and
who had an AECB clinically thought to be caused by a
bacterial pathogen. Patients with a diagnosis of chronic
obstructive pulmonary disease (COPD) were also accepted.
Patients with mild to moderate respiratory exacerbations
were entered into the study and categorized as Types I, II,
and III [as defined by the American Thoracic Society (2)
and Anthonisen et al. (5)]. The acute nature of the infection
was documented by recent increases of bronchopulmonary
symptoms and laboratory evidence of lower respiratory
tract bacterial infection. In order to be eligible for study
participation, the patient must have had increased purulent/
mucopurulent sputum and at least one of the following:
increased cough, increased dyspnea, increase of sputum
volume, or presence of fever (oral temperature410048F or
388C).
Patients were excluded for the following reasons: allergy
or severe adverse reactions to carboxyquinolone derivatives
or macrolide derivatives; pregnancy or lactating; history of
severe cardiac failure [class IV of the New York Heart
Association (NYHA) classification]; severe respiratory tract
infections requiring parenteral antimicrobial therapy or
mechanical ventilatory support; chest X-ray suggestive of a
new pneumonia; evidence of significant liver or renal
impairment; or needed a concomitant antibacterial agent
with a spectrum of activity similar to the study drugs.
Prospective patients were also excluded if they received
drugs known to aect QT interval (e.g. terfenadine,
astemizole, etc.); or received previous therapy with a
systemic antibiotic for more than 24 h prior to enrollment.
Adjunctive medications such as bronchodilators, mucoly-
tics, or expectorants were administered as per usual
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approved by each investigator’s institutional review board
and all patients gave written informed consent prior to
enrollment.
STUDY DRUGS AND LABORATORY
ASSESSMENTS
Patients were randomized in blinded fashion at the first visit
in a 1:1:1 ratio to moxifloxacin 400 mg once daily for
5 days, moxifloxacin 400 mg once daily for 10 days, or
clarithromycin 500 mg bid for 10 days based on a
randomization code that was computer generated by the
Bayer Corporation. Following random assignment to
treatment, patients took two encapsulated tablets twice
daily at approximately the same time of day with 120 ml
(4 oz) of water, with or without food. Patients were
randomized to either oral moxifloxacin 400 mg adminis-
tered once daily for either 5 or 10 days or clarithromycin
500 mg bid for 10 days. For the purpose of study blinding,
the patients taking moxifloxacin received placebo to
maintain uniform dosing. All drugs were encapsulated in
opaque gelatin capsules for blinding purposes. At the end
of therapy, each patient was questioned regarding the
number of capsules taken during the study in order to
document patient compliance.
Standardized clinical assessment and bacteriological
evaluation (Gram stain and sputum culture) were per-
formed pre-therapy, during therapy (days 3–5), at the end
of therapy visit (post-therapy days 0–6) and at the follow-
up visit (post-therapy days 7–17). Disk diusion and broth
microdilution susceptibility testing were performed accord-
ing to NCCLS guidelines (20,21). Haemophilus spp. andM.
catarrhalis also were tested for -lactamase production. S.
pneumoniae was tested for penicillin susceptibility, either by
oxacillin disk or by penicillin Etest strip. ECGs were
performed prior to initiation of study drug therapy and
once during therapy on days 3–5.
Two populations were evaluated in this trial: patients
with a pretherapy pathogen for whom drug ecacy could
be evaluated (ecacy-valid population; see below) and all
randomized patients who received study drug (intent-to-
treat population) for drug safety evaluation.
EFFICACY/SAFETY MEASUREMENTS
The objective of this study was to demonstrate equivalence
of the three treatment regimens with respect to bacterio-
logical and clinical responses. The end points were
bacteriological and clinical response at the end of therapy
(post-therapy days 0–6) and at follow-up (7–17 days post-
therapy), as well as overall response (defined below) for
those patients with a pretherapy pathogen.
For a course of therapy to be judged valid for ecacy
(i.e. ecacy valid population), the following criteria were
met: ABECB confirmed both by appropriate history of
underlying disease and presentation with symptoms of
acute infection; pneumonia excluded radiologically; pre-
therapy organism isolated and identified from pretherapysputum culture; study drug given for at least 48 h if a
clinical failure, or for at least 5 days if a clinical success; no
concurrent administration of non-study antimicrobial
agents, unless the patient was a treatment failure or relapse;
and at least 80% compliance with study drug regimen.
Clinical response was based on serial examinations of the
patient using the following parameters: objective signs of
auscultatory findings (rales, rhonchi, wheezing, breath
sounds); prolongation of expiratory phase; presence of
fever 4388C; and presence of WBC412 000 cells mm73;
and subjective symptoms of chest pain or discomfort;
change in cough frequency and severity; sputum character-
istics (thickness and volume); and dyspnea. At the end of
therapy, clinical response was graded as ‘clinical cure’
[disappearance of acute signs and symptoms related to the
infection (complete return to a stable pre-exacerbation
condition) or sucient improvement such that additional
or alternative antimicrobial therapy was not required],
‘clinical failure’ (insucient lessening of the signs and
symptoms of infection such that additional or alternative
antimicrobial therapy was required), or ‘indeterminate’
(clinical assessment was not possible to determine for any
reason). The clinical response at the follow-up visit was
reported as: ‘continued clinical cure’ (disappearance of
acute signs and symptoms of infection or continued
improvement where additional or alternative antimicrobial
therapy was not required), ‘clinical recurrence’ [reappear-
ance of signs and symptoms of an acute exacerbation of
bronchitis considered related to an infectious (bacterial)
process such that reinstitution of antimicrobial therapy was
required], or ‘indeterminate’ (patients in whom a clinical
assessment was not possible to determine). Overall clinical
response was also determined based on a summation of end
of therapy and follow-up visit evaluations. Overall clinical
resolution occurred if the patient’s end of therapy response
was resolution or indeterminate with a follow-up evaluation
of continued resolution. Overall clinical failure was
considered in patients with either an end of therapy
evaluation of failure or a follow-up evaluation of recur-
rence.
Bacteriological response was based on the results of
cultures taken before and after therapy. At the end of
therapy, the bacteriological responses were graded as
eradication, presumed eradication (if no material was
available due to a clinical success), persistence, persumed
persistence (no material was available in a patient
considered a clinical failure), or indeterminate (if bacte-
riological response to the study drug was not evaluable for
any reason). In addition, superinfection was defined as
isolation of a new pathogen in a symptomatic patient. For
patients with an end of therapy response of eradication or
presumed eradication, follow-up bacteriological eradication
was defined as: continued eradication, continued presumed
eradication, relapse (original causative organism present),
reinfection (new causative organism identified) and inde-
terminate (not evaluable for any reason).
All patients receiving at least one dose of study drug were
evaluable for safety (intent-to-treat population). Safety was
evaluated on the basis of physical examination findings,
ECGs, adverse events, intercurrent illness and laboratory
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urinalysis tests. Investigators rated each adverse event
subjectively according to relationship to study drug
(probable, possible, remote, or none) and severity (mild,
moderate, severe, or serious or life threatening).
STATISTICAL ANALYSES
The primary goal of the study was to determine whether
moxifloxacin, given for 5 days or for 10 days, was
equivalent to clarithromycin in patients with ABECB. A
priori ordered hypotheses were constructed and a sequen-
tially rejective multiple test procedure was planned. If a test
of non-equivalence of 10-day moxifloxacin vs. clarithromy-
cin was rejected, then a test of the 5-day regimen would be
performed. This multiple test procedure would keep the
overall significance level at alpha0.05 for two-sided tests
of the primary ecacy variable.
For each evaluation of clinical and bacteriological
response, a two-sided 95% confidence interval for the
weighted dierence between treatment groups was con-
structed using Mantel–Haenszel weights (weighting by
center). Equivalence was defined as the lower limit of the
two-sided 95% confidence interval for the dierence
between groups being greater than715%. With the sample
size of 420 ecacy-valid patients enrolled, the study had a
power of 90% to test the null hypothesis of inequivalence,
assuming a failure rate of 15% for each treatment group.
For categorical variables, a chi-squared test was used to
test for the dierences between groups. For continuous
variables, a one-way analysis of variance was used, with a
term included for treatment. Comparisons of the incidence
rates of adverse events between the three study drug groups
were done descriptively. Events were tabulated by type
(according to the COSTART glossary) and frequency for
all adverse events and for those events considered to be
related to drug treatment.
Results
Of the 936 patients enrolled, 491 (52%) had a pathogen
isolated pretherapy. Nine hundred and twenty-six (99%)
patients comprised the intent-to-treat population. Ten
patients were excluded from the intent-to-treat analysis
because they were lost to follow up after the initial visit.
Eight hundred and thirty-seven patients completed the
study (284 in the 5-day moxifloxacin group, 277 in the 10-
day moxifloxacin group and 276 in the clarithromycin
group). Among 99 patients who failed to receive a full
course of study drug, adverse events were the main reason
for premature discontinuation of treatment across the
regimens (47%; see safety section below). Four hundred
and twenty patients with a pretherapy organism were valid
for the ecacy analysis (143 5-day moxifloxacin group, 148
10-day moxifloxacin group and 129 clarithromycin). The
most common reasons for exclusion from the ecacy
analysis were: no pretherapy organisms (n337), essential
data missing or invalid (n44), violating of inclusion/
exclusion criteria (n44), insucient duration of therapy(n29), lost to follow up (n29), or non-compliance with
study drug (n29).
As shown in Table 1, the three treatment groups who
comprised the ecacy-valid population were well matched
with regard to age, gender, ethnic origin, smoking history
and infection type. The majority of patients enrolled were
males (mean age, 55 years) and patients experienced an
average of 26 treated AECBs during the past year. Ninety
percent had a history of present or past smoking (mean
32 yr). Over 75% of ecacy-valid patients presented with
Type 1 infections (Table 1). Baseline demographic and
clinical characteristics of the intent-to-treat group were
similar to those considered to be ecacy-valid, with the
exception of the average number of cigarettes smoked
(P0036). Patients in the two moxifloxacin groups
averaged between two and three more cigarettes per day
than those in the clarithromycin group.
CLINICAL RESPONSE
Table 2 illustrates the clinical and bacteriological success
rates for the three populations of patients analyzed at the
various timepoints assessed during the study. The overall
clinical response rates for the ecacy-valid group were 89%
for the 5-day moxifloxacin and 91% for the clarithromycin
regimens (95% CI787%, 42%). For the 10-day
moxifloxacin group, the overall clinical response rate was
91% (95% CI for 10-day moxifloxacin minus clar-
ithromycin759%, 68%). Thus, both moxifloxacin regi-
mens were found to be statistically equivalent to the
clarithromycin regimen. Furthermore, baseline demo-
graphic characteristics did not appear to influence the
success rates for the treatment groups.
For the ecacy-valid group, 16 (9%) of the 5-day
moxifloxacin, 14 (11%) of the 10-day moxifloxacin and 11
(9%) of the clarithromycin recipients were determined to be
clinical failures. Overall clinical failure was associated with
bacteriological persistence or recurrence for five (3%) 5-day
moxifloxacin, six (4%) 10-day moxifloxacin and five (4%)
clarithromycin-treated patients.
BACTERIOLOGICAL RESPONSE
The overall bacteriological response rates by patient for the
ecacy-valid group were 89% (127/143) for the 5-day
moxifloxacin and 85% (110/129) for the clarithromycin
regimens (95% CI737%, 105%) (see Table 2). For the
10-day moxifloxacin group, the overall bacteriological
response rate was 91% (135/148; 95% CI for 10-day
moxifloxacin minus clarithromycin03%, 145%). Thus,
both moxifloxacin regimens were found to be statistically
equivalent to the clarithromycin regimen with respect to
bacteriological response. Overall organism eradication
rates, including presumed eradication, at the end of therapy
were 94% (127 of 135) for 5-day moxifloxacin, 95% (138 of
145) for 10-day moxifloxacin and 91% (115 of 127) for
clarithromycin therapy. Corresponding rates at the
7–17 day post-therapy follow-up visit were 89% (127 of
143), 91% (135 of 148) and 85% (110 of 129), respectively.
TABLE 1. Demographics and baseline medical characteristics




















Mean+SD 569+154 562+158 555+160 566+155 550+161 542+159
Range 19–89 18–88 18–90 21–89 23–84 19–87
Sex, n (%) male 169 (54) 160 (53) 158 (51) 87 (61) 78 (53) 78 (60)
Race, n (%) Caucasian 237 (76) 228 (75) 229 (73) 97 (68) 99 (67) 78 (60)
Type of AECB infection per
Anthonisen (5), n (%)
I 239 (77) 231 (76) 247 (79) 109 (74) 109 (74) 106 (82)
II 69 (22) 65 (22) 59 (19) 33 (23) 38 (26) 21 (16)
III 4 (1) 6 (2) 6 (2) 1 (51) 1 (51) 2 (2)
Mean number (%) of
exacerbations in past 12 months
27 27 27 27 26 25
Concomitant systemic steroid
therapy, n (%)
75 (24) 59 (20) 74 (24) 32 (22) 26 (18) 25 (19)
History of cigarette smoking,
past or present
n (%) 269 (86) 252 (83) 127 (89) 275 (88) 129 (87) 118 (91)
Length of history (yrs) 325 337 324 273 289 272
Average number cigarettes
smoked per day
n 267 250 273 126 128 118
Mean 267 275 245 273 289 272
*includes patients who had pretherapy pathogen.
TABLE 1A. Pre-therapy signs and symptoms
5-day Moxifloxacin 10-day Moxifloxacin Clarithromycin
N143 N148 N129
n/N (%) n/N (%) n/N (%)
Presence of wheezes 92 (64) 106 (72) 88 (68)
Rales 35 (25) 28 (19) 29 (23)
Rhonchi 99 (69) 115 (78) 97 (75)
Expiration prolonged 80 (56) 94 (64) 72 (56)
Decreased breath sounds 51 (36) 55 (37) 53 (41)
Patients with symptoms
increased from baseline*
Sputum volume 141 (99) 142 (96) 124 (96)
Sputum purulence /thickness 143 (100) 148 (100) 128 (99)
Cough frequency 141 (99) 145 (98) 127 (98)
Chest discomfort 82 (57) 70 (47) 74 (57)
Dyspnea 110 (77) 114 (77) 110 (85)
*Baselinestatus between exacerbations
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were clinical failures were as follows for 5-day moxiflox-
acin: S. aureus—1, K. pneumoniae—2, E. cloacae—1, P.
auruginosa—4, M. catarrhalis—5, H. influenzae—4; for10-day moxifloxacin: S. aureus—2, Streptococcus Sp.—1, S.
pneumoniae—2, E. coli—1, E. aerogenes—1, S. marces-
cens—1, C. freundii—1, P. auruginosa—4, M. catarrhalis—
2, H. influenzae—3; and for 10-day clarithromycin: S.
TABLE 2. Clinical and bacteriological success rates
5-day Moxifloxacin 10-day Moxifloxacin Clarithromycin
n/N (%) n/N (%) n/N (%)
Ecacy-valid patients
Clinical Success
End of therapy (0–6 days post-therapy) 127/135 (94) 136/144 (94) 121/127 (95)
Follow-up (7–17 days post-therapy) 127/135 (94) 134/140 (96) 118/123 (96)
Overall* 127/143 (89) 134/148 (91) 118/129 (91)
Bacteriological Success
End of therapy (0–6 days post-therapy) 127/135 (94) 138/145 (95) 115/127 (91)
Follow-up (7–17 days post-therapy) 127/143 (89) 135/148 (91) 110/129 (85)
Intent-to-treat patients
Clinical Success
End of therapy (0–6 days post-therapy) 274/288 (95) 266/281 (95) 268/286 (94)
Follow-up (7–17 days post-therapy) 242/256 (94) 250/258 (97) 232/245 (95)
Overall* 242/270 (90) 250/273 (92) 232/263 (88)
Bacteriological Success
End of therapy (0–6 days post-therapy) 142/152 (93) 156/165 (95) 130/144 (90)
Follow-up (7–17 days post-therapy) 130/149 (87) 144/159 (91) 113/136 (83)
*Overall response includes failures occurring at end of therapy which are carried forward in addition to clinical evaluations at
the follow-up timepoint. Indeterminates were excluded from the denominator at the end of therapy timepoint. The dierence
between the overall denominator and the end of therapy denominator represents the number of indeterminates at end of
therapy.
MOXIFLOXACIN 5-DAY THERAPY BRONCHITIS 23aureus—2, S. pneumoniae—3, N. meningitidis—1, P. mir-
abilis—1, P. auruginosa—1, H. influenzae—5 and K.
pneumoniae—1.
There were 12 superinfections in total, five among the
ecacy-valid patients (three of the 5-day moxifloxacin-
treated patients and two of the clarithromycin-treated
patients). In addition, among the total patient population,
four patients in the 5-day moxifloxacin group, one patient
in the 10-day moxifloxacin and seven patients in the
clarithromycin group who had negative cultures initially
and positive cultures at the follow-up visit. Reinfections or
recurrences were reported for seven and ten patients in the
5-day and 10-day moxifloxacin, respectively, compared to
10 clarithromycin recipients. Three of the four 5-day
moxifloxacin superinfections and three of the six 10-day
moxifloxacin reinfections were due to S. pneumoniae. H.
influenzae or H. parainfluenzae accounted for four of the
seven clarithromycin superinfections and two of the five
clarithromycin recurrences.
Five hundred and twenty-nine pathogens were isolated
pretherapy from 420 ecacy-valid patients. H. influenzae,
M. catarrhalis and S. pneumoniae were isolated from 21%,
16% and 11% of ecacy-valid patients at study entry. H.
parainfluenzae, S. aureus and K. pneumoniae were isolated
from 9%, 8% and 9% of ecacy-valid patients at study
entry. Among 110 H. influenzae isolates, nine produced
beta-lactamase and of 60 pneumococcal isolates, five were
found to be penicillin-resistant based on MIC data. Among
85 M. catarrhalis isolates, 56 produced beta-lactamase.
Based on our definition of bacteriological response,
bacteriological eradication for H. influenzae was reportedfor 89%, 97% and 76% of isolates in the 5-day
moxifloxacin, 10-day moxifloxacin and clarithromycin
regimens, respectively. Corresponding rates of eradication
for M. catarrhalis were 85%, 96% and 100%. For S.
pneumoniae, 5-day and 10-day moxifloxacin regimens
eradicated 100% and 95% of organisms compared to
91% in the clarithromycin group. One hundred percent of
H. parainfluenzae isolates were eradicated by all three
treatment regimens. The individual eradication rates at the
end of study and end of therapy are shown in Table 3.
SAFETY
The safety population comprised 926 patients (312 5-day
moxifloxacin, 302 10-day moxifloxacin and 312 clarithro-
mycin). Clarithromycin-treated patients reported slightly
more treatment-emergent events (48%) then the 5-day
moxifloxacin (42%) or 10-day moxifloxacin (46%) groups.
Forty-seven (5%) patients (4% 5-day moxifloxacin, 4% 10-
day moxifloxacin and 7% clarithromycin) were prematurely
discontinued from the study due to 95 adverse events. In
both moxifloxacin groups, gastrointestinal events (n16)
were the most frequent reason for early discontinuation of
study drug. Similarly, for clarithromycin recipients, gastro-
intestinal-related adverse were most often reported (n12).
Drug-related events were reported by 26% of 5-day
moxifloxacin, 30% of 10-day moxifloxacin and 33% of
clarithromycin-treated patients. Events occuring in at least
2% of the study population and considered to be drug-
related are summarized in Table 4. Among these patients,
TABLE 3. Eradication rates for the most common pre-treatment organisms isolated
5-day Moxifloxacin 10-day Moxifloxacin Clarithromycin
n/N (%) n/N (%) n/N (%)
End of therapy (0–6 days post-therapy)
Haemophilus influenzae 37/37 (100) 32/32 (100) 33/40 (83)
Moraxella catarrhalis 32/33 (97) 25/25 (100) 24/24 (100)
Streptococcus pneumoniae 15/15 (100) 21/21 (100) 21/23 (91)
Staphylococcus aureus 14/14 (100) 15/15 (100) 8/8 (100)
Klebsiella pneumoniae 18/20 (90) 14/14 (100) 11/11 (100)
Haemophilus parainfluenzae 14/14 (100) 17/17 (100) 14/14 (100)
Follow-up (7–17 days post therapy)
Haemophilus influenzae 33/37 (89) 31/32 (97) 31/41 (76)
Moraxella catarrhalis 29/34 (85) 26/27 (96) 24/24 (100)
Streptococcus pneumoniae 16/16 (100) 20/21 (95) 21/23 (91)
Staphylococcus aureus 15/16 (94) 17/18 (94) 7/8 (88)
Klebsiella pneumoniae 17/20 (85) 14/15 (93) 10/11 (91)
Haemophilus parainfluenzae 16/16 (100) 21/21 (100) 14/14 (100)
TABLE 4. Drug-related adverse occurring in at least 2% of patients
5-day Moxifloxacin 10-day Moxifloxacin Clarithromycin
n (%) n (%) n (%)
Adverse Event n312 n302 n312
Headache 7 (2%) 7 (2%) 2 (51%)
Asthenia 2 (51%) 5 (2%) 3 (51%)
Nausea 12 (4%) 23 (8%) 23 (7%)
Diarrhea 15 (5%) 18 (6%) 15 (5%)
Vomiting 3 (51%) 8 (3%) 9 (3%)
Dyspepsia 7 (2%) 2 (51%) 2 (51%)
Flatulence 4 (1%) 2 (51%) 5 (2%)
Dizziness 9 (3%) 14 (5%) 4 (1%)
Nervousness 2 (51%) 4 (1%) 5 (2%)
Pruritus 3 (51%) 2 (51%) 5 (2%)
Taste perversion 6 (2%) 6 (2%) 26 (8%)
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adverse events reported across all three treatment regimens.
Nausea and vomiting occurred in similar, but higher, rates
in those given 10-day moxifloxacin or clarithromycin
compared to 5-day moxifloxacin recipients. Dizziness was
more often reported in moxifloxacin-treated patients,
whereas taste perversion occurred at a four-fold higher
rate in clarithromycin-treated patients.
Thirty-nine (4%) patients in the safety population were
hospitalized during the study (3% of 5-day moxifloxacin,
4% of 10-day moxifloxacin, 5% of clarithromycin). Forty-
six patients had at least one event that was considered
serious or life threatening (13 5-day moxifloxacin, 15 10-day
moxifloxacin and 18 clarithromycin). For all three regi-
mens, most of the hospitalizations or serious adverse events
were the result of exacerbations of underlying disease and
were considered unrelated to study drug administration.Two deaths occurred during the study period—one 5-day
moxifloxacin and one clarithromycin-treated patient.
Neither death occurred while the patient was receiving the
study drug and neither death was categorized by the
investigator as being drug-related. The patient on moxi-
floxacin died from pancreatitis and the clarithromycin
treated patient died from a presumed myocardial infarc-
tion.
Discussion
AECB is a relatively common condition and bacterial
infection accounts for at least 50% of all episodes.
However, few well designed trials have been conducted to
ascertain optimal antimicrobial therapy in AECB due to
proven bacterial etiology (5). Furthermore, the selection of
MOXIFLOXACIN 5-DAY THERAPY BRONCHITIS 25an ideal agent for ABECB has become more dicult due to
the increasing levels of respiratory tract pathogens that are
-lactam and macrolide-resistant (10,12). Although the
empiric use of antimicrobial treatment for AECB has been
debated, certain high risk groups deserve prompt initiation
of therapy (e.g. those with increasing purulence, dyspnea
and a likely bacterial etiology and patients requiring
hospitalization (9).
One major flaw of many previously conducted trials has
been the attempt to determine the ecacy of anti-
microbials in populations of mixed etiologies, that is,
populations that include those whose exacerbations are of
non-bacterial origin. This practice dilutes any real eect of
the anti-microbial and this is further confused if the
underlying lung disease is poorly defined. In order to truly
assess the benefit of an antimicrobial for the treatment of
ABECB, the patient population should have a documented
bacterial infection by Gram stain criteria (6). Although
empiric therapy is unlikely to be discouraged, it is
important to obtain data on both bacteriological and
clinical ecacy as it is only those patients with bacterial
exacerbations who will benefit from antibiotic therapy.
Then there can be some assurance that if a physician does
treat empirically for AECB of unspecified etiology, the
bacterial exacerbations will be treated appropriately.
To address some of these concerns, but still conform to
the infectious Diseases Society of America’s clinical trial
recommendations for treatment of AECB (23), we pre-
dominantly recruited patients with Type I AECB (75%)
because it is this category of patients who have been shown
to be most likely to benefit from antimicrobial therapy (7).
It should be noted, however, that since only 52% of
enrolled subjects had a bacterial pathogen, these symptoms
alone are not diagnostic for bacterial infection.
We found that the overall clinical response at 7–17 days
post therapy for ecacy-valid patients with a pretherapy
pathogen ranged from 89% to 91% for the three regimens
studied. These rates are generally consistent with the rates
observed in previous fluoroquinolone (24–29) and clari-
thromycin (28–32) studies, although it should be noted that
in some of these studies the ecacy valid population was
not limited to those patients with a pretherapy pathogen.
Because most physicians do not routinely obtain sputum
specimens for bacteriological studies (e.g. Gram stain, etc.)
it is essential that results in real ABECB demonstrate
substantial ecacy. With such evidence, the risk of treating
non-bacterial exacerbations is then limited to the incidence
of adverse events. Physicians should consider the risk of
exposing patients with non-ABECB to potential adverse
events without any benefit. In this study, the most common
adverse events for both moxifloxacin and clarithromycin
were gastrointestinal. In general, both study drugs were well
tolerated. Drug-related adverse events were reported at
comparable rates across the three treatment groups (26% 5-
day moxifloxacin, 30% 10-day moxifloxacin, 33% clari-
thromycin); although, the rate of treatment withdrawals
due to adverse events for the clarithromycin-treated group
was somewhat higher than that for the two moxifloxacin
treated groups (7% clarithromycin vs. 4% 5-day moxiflox-
acin and 4% 10-day moxifloxacin).One limitation of the current trial is the lack of
information on long-term relapse rates. While short-term
relapse rates were low following all three treatment
regimens (4%), continued follow-up for greater than 31
days was not required as part of this registration trial.
Determination of the infection-free interval (i.e. time from
end of one exacerbation to the beginning of the next
exacerbation) is a valuable tool for defining important
dierences in antimicrobial regimens (5), and further
studies should be considered to accurately determine
the infection-free interval for moxifloxacin, comparing 5
and 10 day courses. Clarithromycin, which demonstrates a
reasonable short-term response rate, has been shown to
have a relatively short infection-free interval (28). In the
future, studies should be designed to evaluate if shortening
the course of therapy would aect the infection-free
interval.
The optimal duration of antimicrobial therapy for
ABECB is unknown, although the administration of at
least 10–14 days of therapy has been recommended (4,5).
Levofloxacin, grepafloxacin and trovafloxacin have each
been evaluated in regimens as short as 7–10 days with
acceptable rates of early clinical success (490%) (33–36).
Another recent study has demonstrated the eectiveness of
short course therapy for AECB with clinical success rates
comparable to those achieved here. In that study, a 3-day
course of azithromycin was clinically and microbiologically
equivalent to 10-day amoxicillin clavulanate in patients
with Type I ABECB (37). The validity of the conclusions
from these studies (33–37) however is questionable, given
that none compared short-course to long or conventional
course treatment schedules using pathogen-positive acute
bacterial exacerbations and all were designed to show
equivalence to comparator agents. Investigations to deter-
mine which categories of chronic bronchitis patients could
be appropriate for short-course treatment would be
required to clarify this issue. Short-course treatment regi-
mens may improve patient compliance, reduce the risk of
adverse events, provide potential cost savings and possibly
reduce the pressures that drive antibiotic resistance (38).
Our data support the use of both 5-day and 10-day
moxifloxacin for the treatment of ABECB; clinical and
bacteriological success rates approached 90% following this
regimen. Moreover, because the 5-day and 10-day moxi-
floxacin regimens were clinically and bacteriologically
equivalent to 10-day clarithromycin, 5-day moxifloxacin
may be a preferred regimen for some patients. Nonetheless,
surveillance of resistance patterns must be ongoing in order
to assist physicians in prescribing the most appropriate
antimicrobial.
Ideal antibiotic therapy for ABECB should rapidly
resolve the infection and eradicate the most commonly
isolated respiratory pathogens. As expected H. influenzae
followed by M. catarrhalis and S. pneumoniae were the
most frequently isolated organisms from our ecacy-valid
population. The numbers of each specific type of bacteria
were too small to detect statistically significant dierences
in bacteriological outcome across the three treatment
groups. Although not a statistically significant result, it is
worth noting that both moxifloxacin regimens had higher
26 S. CHODOSH ET AL.eradication rates against H. influenzae compared to
clarithromycin. Clarithromycin’s relatively poor ability
to eradicate H. influenzae has been reported previously (28).
In summary, this trial has demonstrated that patients
with ABECB can be as safely and eectively treated with 5
or 10 days of moxifloxacin as compared to a standard
course of clarithromycin. The shorter course moxifloxacin
may prove to be a convenient once-daily treatment regimen
for this patient population.
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